Paresh Dandona MD Physician

Endocrinology•Buffalo, NY

Distinguished Professor, Head Division of Endocrinology, State University of New York at Buffalo

Join to View Full Profile

3 Gates CirDiabetes Center of WnyBuffalo, NY 14209
Phone+1 716-887-4069
Fax+1 716-887-4773

Education & Training

All India Institute of Medical SciencesClass of 1965

Certifications & Licensure

NY State Medical License 1994 - 2026

Awards, Honors, & Recognition

Buffalo Spree Magazine Castle Connolly, 2006, 2008, 2013-2014
Fellow (FACE) American Association of Clinical Endocrinology
Fellow (FACC) American College of Cardiology

Clinical Trials

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Start of enrollment: 2006 Jul 01
Completed
Phase 4
Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. Start of enrollment: 2007 Feb 01
Terminated
Phase 4
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism Start of enrollment: 2007 Jun 01
Terminated
Not Applicable
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects Start of enrollment: 2008 Mar 01
Completed
Not Applicable
Testosterone Replacement in Men With Diabetes and Obesity Start of enrollment: 2010 May 01
Completed
Phase 4
The Suppression of Toll Like Receptors by Insulin Start of enrollment: 2008 Sep 01
Completed
Not Applicable
Exeantide in Type 2 Diabetes on Insulin Start of enrollment: 2008 Apr 01
Completed
Phase 2
Resveratrol in Type2 Diabetes and Obesity Start of enrollment: 2008 Dec 01
Terminated
Not Applicable
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
Completed
Phase 4
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus Start of enrollment: 2010 Oct 01
Completed
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes Start of enrollment: 2012 Nov 01
Withdrawn
Phase 3
Liraglutide in Type 1 Diabetes Start of enrollment: 2012 Nov 01
Completed
Phase 3
Liraglutide in the Treatment of Type 1 Diabetes Mellitus Start of enrollment: 2012 Nov 01
Completed
Phase 3
Sitagliptin in Type I Diabetic Patients Start of enrollment: 2011 Jun 01
Withdrawn
Not Applicable
Liraglutide In Overweight Patients With Type 1 Diabetes Start of enrollment: 2012 Dec 01
Completed
Phase 3
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin Start of enrollment: 2015 Nov 01
Completed
Phase 4
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes Start of enrollment: 2016 Mar 01
Completed
Not Applicable
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes Start of enrollment: 2016 Nov 01
Completed
Not Applicable
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes Start of enrollment: 2017 Jan 10
Terminated
Phase 4
Triple Therapy in T1DM Start of enrollment: 2019 May 01
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Anti-inflammatory Effects of the Fiber Start of enrollment: 2016 Jun 14
COMPLETED
NA
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Use of glucagon-like peptide-1 receptor agonists in people with history of acute pancreatitis: TriNetX analysis.
Mahmoud Nassar, Hazem Abosheaishaa, Anoop Misra, Paresh Dandona, Husam Ghanim
Diabetes & Metabolism. 2025-03-01
2 citations
Diabetes surpasses obesity as a risk factor for low serum testosterone level.
Samir H Assaad Khalil, Paresh Dandona, Nermin A Osman, Ramy Samir Assaad, Basma Tayseer Abdalla Zaitoon
Diabetology & Metabolic Syndrome. 2024-06-28
Glucose ingestion does not lower testosterone concentrations in men on testosterone therapy.
Sandeep Dhindsa, Husam Ghanim, Michael J McPhaul, Amit K Ghoshal, Paresh Dandona
Journal of Investigative Medicine. 2024-06-01

Journal Articles

Hypogonadotropic Hypogonadism in Men with Diabesity
Sandeep Dhindsa, Paresh Dandona, Diabetes Care

Lectures

New Treatments for Type 1 Diabetes and the Pathophysiology of Microvascular Complications
ENDO 2019 - New Orleans, LA - 3/24/2019

Press Mentions

Make It WorkFebruary 10th, 2025
Deficiency That Affects Nearly 40% of Men over 45 May Double Risk of Severe Covid - StudySeptember 10th, 2022
Low Testosterone May Raise Risk of COVID HospitalizationSeptember 9th, 2022
Join now to see all

Grant Support

Testosterone Effects On Insulin Sensitivity &Inflammation In T2dm And ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases2011
Hypogonadotropic Hypogonadism, Insulin Sensitivity And Inflammation In Type 2 DIANational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
Inflammation In Obesity: Modulation By Weight LossNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009